Enable more effective and targeted treatments that address unique needs for patients with pharmacogenomics. The traditional one-size-fits-all approach to medication has long been recognized as a ...

Pharmacogenomic testing for antidepressants could help reduce the time and cost it takes to find the most effective medication for a patient, according to a new study. Scientists developed a ...

New Orleans-based Ochsner Health was met with some uncertainty when it launched its pharmacogenomic program in March 2022 and became one of the first health systems to standardize genomic testing.

Pharmacogenomic testing, a mature and growing aspect of personalized medicine, has demonstrated significant ability to enhance health outcomes and reduce healthcare costs. Since the 1970s, ...

Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...

Two major Australian health insurers, Bupa and Medibank, have started offering genetic testing meant to tell you your likely reaction to certain medications. Subscribe to our newsletter for the latest ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LAS VEGAS -- ...

A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient ...

Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug ...

Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men. The standard treatment for advanced PC often involves androgen deprivation therapy ...